IgG Patient (n) Control (n) Za P b CD25a Squamous 0.69±0.17(87) 0.52±0.16 (200) -7.55 <0.001 Adenocarcinoma 0.64±0.18(124) 0.52±0.16 (200) -5.88 <0.001 Squamous 0.40±0.21(87) 0.43±0.22(200) -1.31 0.19 Adenocarcinoma 0.36±0.22( 124) 0.43±0.22(200) -4.22 <0.001 CD25c Squamous 1.11±0.34(87) 1.14±0.32(200) -0.70 0.49 Adenocarcinoma 1.06±0.29( 124) 1.14±0.32(200) -1.95 0.05 FOXP3 Squamous 0.62±0.21(87) 0.52±0.24(200) -4.32 <0.001 Adenocarcinoma 0.59±0.25( 124) 0.52±0.24(200) -2.71 0.007 Plasma IgG levels are expressed as mean ± SD in SBR. a Mann–Whitney U test (two-tailed); b.P <0.0125 was considered to be statistically significant as four individual antigens were tested. Table 4. The levels of circulating antibodies against CD25 and FOXP3 in four groups of NSCLC
IgG Patient (n) Control (n) Za P b CD25a Squamous 0.69±0.17(87) 0.52±0.16 (200) -7.55 <0.001 Adenocarcinoma 0.64±0.18(124) 0.52±0.16 (200) -5.88 <0.001 Squamous 0.40±0.21(87) 0.43±0.22(200) -1.31 0.19 Adenocarcinoma 0.36±0.22( 124) 0.43±0.22(200) -4.22 <0.001 CD25c Squamous 1.11±0.34(87) 1.14±0.32(200) -0.70 0.49 Adenocarcinoma 1.06±0.29( 124) 1.14±0.32(200) -1.95 0.05 FOXP3 Squamous 0.62±0.21(87) 0.52±0.24(200) -4.32 <0.001 Adenocarcinoma 0.59±0.25( 124) 0.52±0.24(200) -2.71 0.007 Plasma IgG levels are expressed as mean ± SD in SBR. a Mann–Whitney U test (two-tailed); b.P <0.0125 was considered to be statistically significant as four individual antigens were tested. Table 4. The levels of circulating antibodies against CD25 and FOXP3 in four groups of NSCLC
Final_version_of_manuscript.docx